Rodman & Renshaw Assumes Can Fite Biopharma Ltd (ADR) to Buy

Brokerage firm Rodman & Renshaw Assumes its rating on Can Fite Biopharma Ltd (ADR)(NYSEMKT:CANF). The shares have been rated Buy. The rating by Rodman & Renshaw was issued on Aug 29, 2016.

Can Fite Biopharma Ltd (ADR) (CANF) shares turned negative on Thursdays trading session with the shares closing down -0.01 points or -0.40% at a volume of 65,318. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $2.5. The peak price level was also seen at $2.5 while the days lowest was $2.42. Finally the shares closed at $2.47. The 52-week high of the shares is $7.85 while the 52-week low is $1.61. According to the latest information available, the market cap of the company is $35 M.

Can Fite Biofarma Ltd is an Israel-based biopharmaceutical company. The Company develops new treatments for autoimmune diseases and cancer. The Company’s drugs are CF101 for Psoriasis treatment RA treatment for the treatment of Keratoconjunctictivitis Sicca for the treatment of Glaucoma among others; and CF102 for the treatment of liver diseases. The Company has a research infrastructure including research laboratories and animal house facilities run by the development team. Can Fite Biofarma Ltd signed distribution contracts with a Kwang Dong Pharmaceutical Co. allowing distribution of CF101 for arthritis in Korea and Seikagaku Corp. for distribution in Japan. The Company operates three subsidiaries Ultratrend Ltd EyeFite Ltd and OphathaliX Inc.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *